Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius Medical Care AG & Co. KGaA

Investor Presentation • Feb 24, 2010

165_ip_2010-02-24_f2aa632f-4b54-4ceb-9ac5-2e1aee121b5b.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Fresenius Medical Care

The World's Leading Renal Therapy Company

2009 4th Quarter / Fiscal Year Results

Analyst Meeting, February 24, 2010

Safe Harbor Statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) reports filed with the Securities and Exchange Commission (SEC) and the German Exchange Commission (Deutsche Börse).

1. Business Update

2. Financials and Outlook

3. Questions & Answers

Fiscal Year 2009

Record results

\$
U
S
i
i
l
l
i
n
m
o
n
s
-		 I
d
i
d
m
p
r
o
v
e
g
u
a
n
c
e
f
Q
3
2
0
0
9
a
s
o		 R
d
t
e
p
o
r
e
N
t
e
r
e
e
n
e
s
v
u		 \$
1
1
2
0
0
~
,		 \$
1
1
2
4
7
,
N
i
t
e
n
c
o
m
e		 \$
8
6
8
9
0
5
-		 \$
8
9
1
t
tr
i
bu
ta
b
le
to
F
M
C
A
G
&
Co
K
Ga
A
a
L
i
t
e
e
r
a
g
e
r
a
o
v
(
D
b
/
E
B
I
T
D
A
)
t
e		 2
7
<		 2
5
C
i
t
l
d
i
t
a
p
a
e
x
p
e
n
u
r
e
s		 \$
5
5
0
6
5
0
~
-		 \$
5
6
2
A
i
i
i
t
c
q
s
o
n
s
u		 \$
2
0
0
3
0
0
~
-		 \$
1
8
8

Strong momentum in the 4th quarter

1st time above US\$ 3 billion in revenues for a quarter

Q
4
2
0
0
8		 Q
4
2
0
0
9		 G
h
t
r
o
w
R
e
v
e
n
u
e		 \$
2
2
2
7
m
,		 \$
3
0
3
5
m
,		 1
2
%
+
N
i
t
e
n
c
o
m
e
t
tr
i
bu
ta
b
le
to
F
M
C
A
G
&
Co
K
Ga
A
a		 \$
2
1
4
m		 \$
2
4
7
m		 1
%
5
+
i
E
h
a
r
n
n
g
s
p
e
r
s
a
r
e		 \$
0
7
2		 \$
0
8
2		 %
1
5
+
  • •Strong revenue growth of +8% at constant currency
  • •EBIT-margin improvement of 30 basis points year-over-year in the fourth quarter
  • •Accelerated net income growth

Fiscal Year 2009 – Revenue

Very strong revenue growth globally

\$
U
S
i
i
l
l
i
n
m
o
n
s
-		 Q
4
2
0
0
8		 Q
4
2
0
0
9		 G
h
t
r
o
w		 c
c
N
h
A
i
t
o
r
m
e
r
c
a		 1
6
3
2
,		 1
9
9
7
,		 1
0
%
I
i
l
t
t
n
e
r
n
a
o
n
a		 3
5
2		 4
2
7		 2
2
%		 1
2
%
T
l
t
o
a		 1
9
8
4
,		 2
2
2
6
,		 1
2
%		 1
1
%
  • •Good organic treatment growth
  • •Strong revenue per treatment growth

Very strong revenue growth globally

\$
S
U
i
i
l
l
i
n
m
o
n
s
-		 F
Y
2
0
0
8		 F
Y
2
0
0
9		 G
t
h
r
o
w		 c
c
i
N
h
A
t
o
r
m
e
r
c
a		 6
2
4
7
,		 6
7
9
4
,		 %
9
I
i
l
t
t
n
e
r
n
a
o
n
a		 1
9
0
4
,		 5
5
1
6
,		 %
4		 1
%
4
T
l
t
o
a		 7
7
3
7
,		 8
3
5
0
,		 8
%		 1
0
%

Treating more than 195,650 patients in ~ 2,550 clinics

Overall strong quality performance

N
h
A
i
(
U
S
)
t
o
r
m
e
r
c
a		 E
M
E
A		 S
T
A
T
U
S
%
f
t
i
t
o
p
a
e
n
s		 Q
2
0
0
8
4		 Q
4
2
0
0
9		 Q
2
0
0
8
4		 Q
4
2
0
0
9
/
K
t
V
1
2
≥		 9
%
5		 9
6
%		 9
%
4		 5
9
%
/
H
l
b
i
1
0
1
2
d
l
e
m
o
g
o
n
g
=
-		 %
6
1		 6
4
%		 %
5
0		 5
2
%
A
l
b
i
3
/
d
l
5
≥
u
m
n
g		 8
0
%		 8
3
%		 8
%
5		 8
8
%		 I
m
p
r
o
v
e
/
P
h
h
t
3
5
5
5
d
l
o
s
p
a
e
m
g
-		 %
5
3		 5
3
%		 %
6
1		 6
1
%		 I
m
p
r
o
e
v
H
i
l
i
i
d
t
t
o
s
p
a
a
o
n
a
s
z
y		 1
0
5		 *
1
0
0		 8
1		 8
6

The hospitalization rates for the US reflects adoption of CMS policy *

* Note that average U.S. nocturnal patient weight was 24% greater than average 3xWeek in-center HD patient weight. ** Dietary phosphorus intake for US nocturnal patients was 22% greater than for average US 3xWeek in-center HD patients.

Excellent performance in all key metrics

Q
4
2
0
0
9		 T
l
t
o
a		 N
h
A
i
t
o
r
m
e
r
c
a		 I
i
l
t
t
n
e
r
n
a
o
n
a
O
i
t
h
r
g
a
n
c
r
e
v
e
n
u
e
g
r
o
w		 1
0
%
+		 1
0
%
+		 9
%
+
S
k
h
t
t
t
t
t
a
m
e
m
a
r
e
r
e
a
m
e
n
g
r
o
w		 3
6
%
+		 3
6
%
+		 3
7
%
+
R
t
t
t
e
v
e
n
u
e
p
e
r
r
e
a
m
e
n		 )
1
\$
3
0
5		 \$
1
3
7
G
t
h
r
o
w		 %
6
+		 %
4
+
c
c
F
Y
2
0
0
9
f
N
b
l
i
i
m
e
r
o
c
n
c
s
u		 2
5
5
3
,		 1
7
8
4
,		 7
6
9
G
t
h
r
o
w		 %
7
+		 6
%
+		 1
0
%
+
D
e
n
o
v
o
s
(
)
in
lu
d
in
d
l
in
ic
c
g
m
a
na
g
e
c
s		 1
2
0		 8
9		 3
1

1) including Mexico

4th Quarter 2009 – Revenue per treatment US

Product growth influenced by lower machine sales

\$
S
U
i
i
l
l
i
n
m
o
n
s
-		 Q
4
2
0
0
8		 Q
4
2
0
0
9		 G
h
t
r
o
w		 c
c
T
l
t
o
a
r
e
v
e
n
u
e
(
inc
l.
In
l
Re
)
te
rn
a
ve
nu
e		 9
6
4		 1
0
6
0
,		 %
1
0		 %
4
E
l
t
e
r
n
a
r
e
e
n
e
x
v
u		 3
8
7		 8
0
9		 1
0
%		 3
%
N
t
h
A
i
o
r
m
e
r
c
a		 2
2
0		 2
1
3		 3
%
-
I
i
l
t
t
n
e
r
n
a
o
n
a		 5
1
8		 5
9
6		 %
1
5		 %
5

Good external product growth of 6%cc

\$
U
S
i
i
l
l
i
n
m
o
n
s
-		 F
Y
2
0
0
8		 F
Y
2
0
0
9		 G
h
t
r
o
w		 c
c
T
l
t
o
a
r
e
e
n
e
v
u
(
inc
l.
In
te
l r
)
rn
a
ev
en
ue		 3
2
8
7
,		 3
8
3
6
,		 3
%		 8
%
E
l
t
x
e
r
n
a
r
e
v
e
n
u
e		 2
8
7
5
,		 2
8
9
7
,		 1
%		 6
%
N
h
A
i
t
o
r
m
e
r
c
a		 7
5
8		 8
1
8		 %
8
I
i
l
t
t
n
e
r
n
a
o
n
a		 2
1
1
7
,		 2
0
7
9
,		 2
%
-		 6
%

2010 Strategic Business Drivers

Drivers for sustained revenue and earnings growth

Dialysis Market Drivers:

  • Continued patient growth of ~ 6% per year
  • Stable to positive dialysis reimbursement based on quality patient outcomes

Expansion & New Product Launches:

  • Renal Pharma
  • Selective Clinic acquisitions
  • Integrated Care Model – Also a challenge
  • New Renal Product Launches worldwide in HD and PD
  • Liberty Cycler continues
  • 2008T Machine, 4008S classic Machine
  • New Phoslyra

Acetate free concentratesBCM for Peritonealdialysis

1. Business Update

2. Financials and Outlook

3. Questions & Answers

\$
i
i
l
l
i
n
m
o
n
s		 Q
4
2
0
0
8		 Q
4
2
0
0
9		 G
h
t
r
o
w
N
t
e
r
e
v
e
n
u
e		 2
7
2
2
,		 5
3
0
3
,		 *
%
1
2
O
(
)
i
i
E
B
I
T
t
p
e
r
a
n
g
n
c
o
m
e		 4
3
3		 4
9
1		 1
3
%
%
E
B
I
T
i
i
m
a
r
g
n
n		 1
5
9		 1
6
2
I
t
t
t
n
e
r
e
s
e
x
p
e
n
s
e
n
e
,		 8
5		 7
5
I
b
f
i
t
n
c
o
m
e
e
o
r
e
n
c
o
m
e
a
x		 3
4
8		 4
1
6		 1
9
%
I
t
n
c
o
m
e
a
e
p
e
n
s
e
x
x		 1
2
0		 1
4
5
T
t
a
x
r
a
e		 3
4
%		 3
5
%
N
l
l
i
i
t
t
t
o
n
c
o
n
r
o
n
g
n
e
r
e
s		 1
4		 2
4
N
i
t
e
n
c
o
m
e
i
bu
b
le
F
M
C
A
G
&
Co
K
Ga
A
t
tr
ta
to
a		 2
1
4		 2
4
7		 1
%
5

* 8% growth at constant currency, 8% organic growth

\$
i
i
l
l
i
n
m
o
n
s		 F
Y
2
0
0
8		 F
Y
2
0
0
9		 G
h
t
r
o
w
N
t
e
r
e
v
e
n
u
e		 1
0
6
1
2
,		 1
1
2
4
7
,		 *
%
6
O
(
)
i
i
E
B
I
T
t
p
e
r
a
n
g
n
c
o
m
e		 1
6
2
7
,		 1
5
6
7
,		 %
5
%
E
B
I
T
i
i
m
a
r
g
n
n		 1
5
8		 1
5
6
I
t
t
t
n
e
r
e
s
e
x
p
e
n
s
e
n
e
,		 3
3
6		 3
0
0
I
b
f
i
t
n
c
o
m
e
e
o
r
e
n
c
o
m
e
a
x		 1
3
3
6
,		 1
4
5
6
,		 9
%
I
t
n
c
o
m
e
a
e
p
e
n
s
e
x
x		 4
7
6		 4
9
1
T
t
a
x
r
a
e		 3
6
%		 3
4
%
N
l
l
i
i
t
t
t
o
n
c
o
n
r
o
n
g
n
e
r
e
s		 4
2		 4
7
N
i
t
e
n
c
o
m
e
i
bu
b
le
F
M
C
A
G
&
Co
K
Ga
A
t
tr
ta
to
a		 8
1
8		 8
9
1		 9
%

* 9% growth at constant currency, 8% organic growth

Operating Margin Development

Page 21

Operating cash flow at 15% of revenue

\$
i
i
l
l
i
n
m
o
n
s		 Q
2
0
0
8
4		 Q
4
2
0
0
9		 G
t
h
r
o
w
1)
O
i
h
f
l
t
p
e
r
a
n
g
c
a
s
o
w		 3
0
1		 4
5
8
1
%
f r
5
o
ev
e
nu
e		 2
%
5
1)
C
i
t
l
d
i
t
t
a
p
a
e
x
p
e
n
u
r
e
s
n
e
,		 (
)
1
8
1		 (
)
1
7
3
F
h
f
l
r
e
e
c
a
s
o
w		 1
2
0		 5
2
8
9
%
f r
o
ev
e
nu
e		 %
1
3
8
1)
A
i
i
i
t
f
d
i
i
c
q
s
o
n
s
t
t
t
u
n
e
o
v
e
s
u
r
e
s
,		 (
8
8
)		 (
)
9
7
1)
f
F
h
l
f
t
i
i
t
i
r
e
e
c
a
s
o
w
a
e
r
a
c
q
s
o
n
s
u
,		 3
2		 2
0
6
%
f r
7
o
ev
e
nu
e

1) A reconciliation to the most directly comparable US-GAAP financial measure is provided in the attachment.

Operating cash flow at 12% of revenue

\$
i
i
l
l
i
n
m
o
n
s		 F
Y
2
0
0
8		 F
Y
2
0
0
9		 G
h
t
r
o
w
1)
O
i
h
f
l
t
p
e
r
a
n
g
c
a
s
o
w		 1
0
1
6
,		 1
3
3
9
,
1
2
%
f r
o
ev
e
nu
e		 %
3
2
1)
C
i
l
d
i
t
t
a
p
a
e
p
e
n
r
e
s
t
x
u
n
e
,		 (
6
3
)
7		 (
)
5
6
2
f
F
h
l
r
e
e
c
a
s
o
w		 3
4
3		 7
7
7
%
f r
7
o
ev
e
nu
e		 1
2
7
%
1)
A
i
i
t
i
f
t
d
i
t
i
t
c
q
u
s
o
n
s
n
e
o
e
s
r
e
s
v
u
,		 (
)
2
1
8		 (
)
1
3
6
1)
F
h
f
l
f
i
i
i
r
e
e
c
a
s
o
t
t
w
a
e
r
a
c
q
u
s
o
n
s
,		 1
2
5		 6
4
1
6
%
f r
o
ev
e
nu
e

1) A reconciliation to the most directly comparable US-GAAP financial measure is provided in the attachment.

Debt/EBITDA ratio ahead of target

* including non-cash charges and in 2006/2007 excluding restructuring costs, in-process R&D and gain from the sale of dialysis clinics. A reconciliation to the most directly comparable US-GAAP financial measure is provided in the attachment.

Major Debt Portfolio and Maturities

Fiscal Year 2010 - OUTLOOK

1. Business Update

2. Financials and Outlook

3. Questions & Answers

Thank You for your interest in Fresenius Medical Care !

Fresenius Medical Care

The World's Leading Renal Therapy Company

2009 4th Quarter / Fiscal Year Results

Analyst Meeting, February 24, 2010

Reconciliation of non US-GAAP financial measures to the most directly comparable US-GAAP financial measure

All numbers are in \$ millions

D
b
t
e		 F
Y
2
0
0
9		 F
Y
2
0
0
8		 F
Y
2
0
0
7		 F
Y
2
0
0
6		 F
Y
2
0
0
5
S
ho
bo
in
(
in
l.
A
/
R
)
t
te
r
rm
rro
w
g
s
c
p
ro
g
ra
m		 3
1
6		 6
8
4		 2
1
7		 3
3
1		 1
1
5
S
fro
ho
t
te
bo
ing
la
te
d
t
ies
+
r
rm
rro
w
s
m
re
p
ar		 1
0		 1 2 5 1
9
Cu
f
t p
t
ion
lon
te
de
b
t a
d
i
ta
l
lea
b
l
ig
t
ion
+
rre
n
or
o
g-
rm
n
ca
p
se
o
a
s		 1
8
5		 4
5
5		 8
5		 1
6
0		 1
2
6
Cu
t p
t
ion
f
Tr
t
Pr
fe
d
Se
i
t
ies
+
rre
n
or
o
us
e
rre
cu
r		 6
7
0
Lo
-te
de
b
t a
d
i
ta
l
lea
b
l
ig
t
ion
+
ng
rm
n
ca
p
se
o
a
s,
les
ion
t p
t
s c
ur
re
n
or		 4,
4
2
8		 3,
9
5
7		 4,
0
0
4		 3,
8
2
9		 7
0
7
Tr
t
Pr
fe
d
Se
i
t
ies
les
t p
t
ion
+
us
e
rre
cu
r
s c
ur
re
n
or		 6
5
6		 6
4
1		 6
6
4		 1,
2
5
4		 1,
1
8
8
To
l
de
b
ta
t
=		 5,
5
6
8		 5,
7
3
8		 5,
6
4
2		 5,
5
7
9		 2,
1
9
1
E
B
I
T
D
A		 F
Y
2
0
0
9		 F
Y
2
0
0
8		 1
)
F
Y
2
0
0
7		 F
Y
2
0
0
6
(
p
ro
for
)
ma		 F
Y
2
0
0
5
La
lve
hs
in
in
(
E
B
I
T
)
t
tw
t
t
s
e
m
on
o
p
er
a
g
co
m
e		 1,
7
5
6		 1,
6
7
2		 1,
5
8
0		 1,
3
6
7		 9
3
9
La
lve
hs
de
ia
ion
d
iza
ion
t
tw
t
t
t
t
+
s
e
m
on
p
re
c
a
n
am
or		 4
5
7		 4
1
6		 3
6
3		 3
2
6		 2
5
1
No
h
ha
+
n-
ca
s
c
rg
es		 0
5		 4
4		 4
1		 3
5		 1
4
E
B
I
T
D
A
(
l
ize
d
)
an
nu
a
=		 2,
2
6
3		 2,
1
3
2		 1,
9
8
4		 1,
7
2
8		 1,
2
0
4

1) Excluding restructuring costs and in-process R&D

Reconciliation of non US-GAAP financial measures to the most directly comparable US-GAAP financial measure

E
l
R
t
e
r
n
a
e
e
n
e
x
v
u		 F
Y
2
0
0
9		 F
Y
2
0
0
8		 t
h
g
ro
w		 cc Q
4
2
0
0
9		 Q
4
2
0
0
8		 t
h
g
ro
w		 cc
I
i
l
du
t r
t
t
n
e
r
n
a
o
n
a
p
ro
c
ev
e
nu
e		 2,
3
7
4		 2,
4
1
9		 2
%
-		 6
%
+		 6
7
8		 5
9
2		 1
4
%		 5
%
+
In
te
l r
rn
a
ev
e
nu
e
-		 (
2
9
5
)		 (
3
0
2
)		 (
8
2
)		 (
7
4
)
Ex
l
t
e
r
n
a
r
e
e
nu
e
v
=		 2,
0
7
9		 2,
1
1
7		 %
2
-		 %
6
+		 5
9
6		 5
1
8		 %
1
5		 %
5
+
N
h
A
i
t
du
t r
o
r
m
e
r
c
a
p
ro
c
ev
e
nu
e		 1,
6
3
4		 1,
3
0
9		 1
2
%
+		 3
8
3		 3
1
7		 3
%
+
In
l r
te
rn
a
ev
e
nu
e
-		 (
6
4
)
5		 (
1
)
5
5		 (
1
0
)
7		 (
1
1
)
5
Ex
l
t
e
r
n
a
r
e
v
e
nu
e
=		 8
1
8		 7
5
8		 8
%
+		 2
1
3		 2
2
0		 3
%
-
T
O
T
A
L
du
t r
p
ro
c
ev
e
nu
e		 3,
8
3
7		 3,
7
2
8		 3
%
+		 8
%
+		 1,
0
6
1		 9
6
4		 1
0
%
+		 4
%
+
In
te
l r
rn
a
ev
e
nu
e
-		 (
)
9
4
0		 (
)
8
5
3		 (
)
2
5
2		 (
)
2
2
6
Ex
t
l
e
r
n
a
r
e
v
e
nu
e
=		 2,
8
9
7		 2,
8
7
5		 %
1
+		 %
6
+		 8
0
9		 7
3
8		 %
1
0
+		 %
3
+
C
i
l
d
i
(
)
t
t
t
a
p
a
e
x
p
e
n
u
r
e
n
e		 F Y
2
0
0
9		 F
Y
2
0
0
8		 Q
4
2
0
0
9		 Q
4
2
0
0
8
Pu
ha
f p
ty
la
t a
d
ip
t
rc
s
e
o
ro
p
e
r
p
n
n
e
q
u
m
e
n
,		 (
5
7
4
)		 (
6
8
7
)		 (
1
7
5
)		 (
1
8
5
)
Pr
d
fro
le
f p
ty
la
t a
d
ip
t
o
c
e
e
s
m
s
a
o
ro
p
e
r
p
n
n
e
q
u
m
e
n
-
,		 1
2		 1
4		 2 4
C
i
i
(
)
l
d
t
tu
t
a
p
a
e
p
e
n
r
e
n
e
x
=		 (
)
5
6
2		 (
)
6
7
3		 (
)
1
7
3		 (
)
1
8
1
C
h
F
l
a
s
o
w		 F
Y
2
0
0
9		 F
Y
2
0
0
8		 Q
4
2
0
0
9		 Q
4
2
0
0
8
Ac
is
i
io
d
In
d
ha
f
in
i
b
le
t
tm
t a
t p
ta
ts
q
ns
a
n
ve
s
e
n
n
ne
rc
s
e
s
o
ng
a
s
s
e
u
u		 (
1
8
8
)		 (
2
)
7
7		 (
9
)
7		 (
1
0
1
)
Pr
d
fro
d
ive
i
t
tu
o
c
e
e
s
m
s
re
s		 2
5		 9
5		 - 1
3
A
i
i
i
f
d
iv
i
t
t
t
tu
c
q
u
s
o
n
s,
n
e
o
e
s
r
e
s		 (
1
3
6
)		 (
2
1
8
)		 (
7
9
)		 (
8
8
)

All numbers are in \$ millions

F
Y
2
0
0
9		 C
i
i
l
n
c
s		 i
P
t
t
a
e
n
s		 T
t
t
r
e
a
m
e
n
s
(
in
i
l
l
io
)
m
n
T
t
l
o
a		 2
5
5
3
,		 1
9
5
6
5
1
,		 2
9
4
G
t
h
r
o
w		 %
7
+		 %
6
+		 %
6
+
N
t
h
A
i
o
r
m
e
r
c
a		 1
7
8
4
,		 1
3
2
2
6
2
,		 1
9
9
G
h
t
r
o
w		 6
%
+		 %
5
+		 4
%
+
I
i
l
t
t
n
e
r
n
a
o
n
a		 7
6
9		 6
3
3
8
9
,		 9
5
G
t
h
r
o
w		 %
1
0
+		 %
9
+		 %
1
0
+
E
u
r
o
p
e		 4
3
5		 3
2
4
0
9
,		 4
8
L
t
i
A
i
a
n
m
e
r
c
a		 1
9
1		 2
0
9
7
3
,		 3
2
A
i
P
i
f
i
s
a
a
c
c
-		 1
4
3		 1
0
0
0
7
,		 1
5

Contacts

Fresenius Medical Care AG & Co. KGaAInvestor RelationsElse Kröner Str. 161352 Bad Homburg v.d.H.

Oliver MaierHead of Investor Relations & Corporate Communications Tel.: +49-(0)6172-609-2601 Fax.: +49-(0)6172-609-2301 Email: [email protected]

Gerrit JostTel.: +49-(0)6172-609-5216 Fax.: +49-(0)6172-609-2301 Email: [email protected]

Terry L. Morris Tel.: +1-800-948-2538Fax.: +1-615-345-5605Email: [email protected] Ordinary shares WKN 578 580ISIN DE0005785802SEDOL1 5129074 DE

Q
1
2
0
1
0
R
l
t
e
s
s
u		 – C
C
f
l
l,
M
4
2
0
1
0
o
n
e
r
e
n
c
e
a
a
y
,
i
A
l
G
l
M
t
n
n
u
a
e
n
e
r
a
e
e
n
g		 – f
/
i
M
1
1
2
0
1
0
F
k
M
t
a
y
r
a
n
u
r
a
n
,
,
Q
2
2
0
1
0
R
l
t
e
s
s
u		 – C
f
C
l
l,
A
3
2
0
1
0
t
o
n
e
r
e
n
c
e
a
g
s
u
u
,
Q
3
2
0
1
0
R
l
t
e
s
u
s		 – C
f
C
l
l,
N
b
2
2
0
1
0
o
n
e
r
e
n
c
e
a
o
v
e
m
e
r
,

For recent updates, please have a look at our webpage. www.fmc-ag.com

CalendarInvestor Relations > Financial Calendar

Annual Report / Quarterly Filings / SEC Filings / Deutsche Börse Filings ... Investor Relations > Publications

Corporate Governance / Sarbanes-Oxley Act / NYSE declaration ... Investor Relations > Corporate Governance

Financing / Analyst Coverage / Consensus estimates / Share data … Investor Relations > Our Shares

Fresenius Medical Care

The World's Leading Renal Therapy Company

2009 4th Quarter / Fiscal Year Results

Analyst Meeting, February 24, 2010

More from Fresenius Medical Care AG & Co. KGaA

Regulatory Filings 2026
Jan 16
Share Issue/Capital Change 2026
Jan 12
Transaction in Own Shares 2026
Jan 9
Share Issue/Capital Change 2025
Dec 29
AGM Information 2025
Dec 22
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 15
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 12
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 8
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 3
Transaction in Own Shares 2025
Dec 1
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.